Today, I finished up 20 years of school/training on my last day as a critical care pharmacy resident. Tomorrow, I start my dream first job as an ICU/ED clinical pharmacist at @The_BMC. (1/x)

Great UConn alumni (@UConnAlumni) event in Boston tonight!

UConn stands alone. They’re the only program in college basketball history to win both the men’s and women’s NCAA championships in the same year. And today, they added another milestone—becoming the first program ever to produce two WNBA/NBA Rookies of the Year in the same

🎬 2nd chapter ...🧵This a thread about 1.3% sodium bicarbonate🧂 (aka isotonic bicarb drip) in critical care. ☝🏻 If you missed the first part about 8.4% bicarb, I would strongly recommend you to read it before moving on 🏃🏻. https://t.co/pInsTgPXjg

every politics tweet on here now is like "trump signs executive order shutting down electrical grid" and all the replies under it are just thank you jesus we have prayed for this

How I Do It: Interpreting Clinical Trial Results Read the full research in the December issue of #journal_CHESTCritCare: https://t.co/9bU8yqxpu5 #MedEd #JournalCHEST

Merry Christmas to evidence based medicine 🎄🎁💉👀

Top 10 Important ICU Papers: Second Half of 2024 From the ICU papers published between July and December 2024, I have selected the top 10 key ones, including RCTs, guidelines, and narrative reviews. I hope you like this list.

Wow!! Look at this new Annexa-I data! Those mRS numbers and VTE data do NOT look good to me….

There is an IV fluids shortage (0.9% MS & LR) due to hurricane Helene. Because of the shortage everyone should stop ordering routine maintenance fluids for the next 2-4 weeks. Because of good medical practice everyone should stop ordering routine maintenance fluids forever.

New SRMA on AA vs 4PCC showing no diff in mortality but increased thrombotic events. Not sure on the TE event numbers they entered from Annexa-I, but still, lots of data included in this open-access analysis https://t.co/qjigGW6vYT

New Letter to Editor re Dobesh et al's AA vs 4PCC review (showing AA's superiority) written by CA pharmacists questioning methodology and therefore results Open access at https://t.co/bFs4Yi0AaE

I honestly don’t know how to interpret a study where 15% of the control group received no therapy. And there is no subgroup analysis excluding these patients? I guess given increased risk of ischemic stroke & no difference in overall NIHSS, maybe a neutral study ??? 🤷‍♂️ (1/2)

It is finally published! Time to read ANNEXA-I, published in @NEJM today! https://t.co/7zga5JmVV8

Now that ANNEXa-I is officially published, are you motivated to add andexanet alfa to your formulary or are you sticking with PCC as your primary reversal agent for factor Xa-inhibitor associated intracerebral hemorrhage?

The debate of milrinone vs. dobutamine will likely continue for the rest of our careers as there is rarely a one-size-fits-all strategy in the ICU. DOREMI-2 might help. This paper complements the chapter on the topic in my book. 🎩 tip to the authors. https://t.co/4Ise540F2X

Interested in working at the busiest level 1 Trauma Center in New England? I’m looking for an ED 7-on/7-off overnight pharmacist to join our team @The_BMC! https://t.co/eJGmQMsmbI Feel free to reach out with any questions! #TwitteRx

Our Letter to the Editor (and response) in @Neurology regarding @AANmember @SCCM @AmerAcadPeds Brain death guidelines. https://t.co/mIYYu2iPlY Determination of Brain death after overdose is complex and toxicologists should be involved. Five half lives not adequate. #MedEd

This is a solid way to convince me to approve meropenem

Here’s a critical care puzzle & illustrates some important cardiopulmonary physiology: These two pictures were taken just an hour apart. What intervention was done in between that changed the respiratory pattern? (Red box) Multiple choice & answers in the 🧵. 1/

Follow us at https://t.co/Uz6hMPni3F!